摘要
目的体外观察罗格列酮对小鼠胚胎成骨细胞增殖和成骨分化的影响。方法于中国科学院上海细胞库购买小鼠胚胎成骨细胞并传代,使用不同浓度下的罗格列酮(1、5μmol/L)处理细胞,对照组用等量二甲亚砜(DMSO);观察不同浓度罗格列酮下小鼠胚胎成骨细胞的细胞增殖状况;使用不同浓度罗格列酮的细胞培养基,培养7、14 d,行碱性磷酸酶染色;细胞培养7 d,Real-time PCR检测转录因子Runx2、成骨标志物碱性磷酸酶、骨钙素基因的表达。结果实验组和对照组相比,小鼠胚胎成骨细胞的细胞增殖能力减弱。随着罗格列酮浓度的升高,碱性磷酸酶染色颜色逐渐变浅。聚合酶链式反应结果显示Runx2 mRNA表达分别下降了(54.7±8.2)%和(52.3±7.2)%,碱性磷酸酶mRNA表达分别下降了(18.7±5.1)%和(37.8±8.5)%,骨钙素mRNA表达分别下降了(43.4±5.6)%和(60.4±4.3)%;差异均有统计学意义(P<0.05)。结论罗格列酮能抑制小鼠胚胎成骨细胞的细胞增殖和成骨细胞分化,这可能就是2型糖尿病患者服用噻唑烷二酮类药物后并发骨质疏松的原因之一。
Objective To study the effect of rosiglitazone （ROSI）, the agonist of peroxisome proliferator activated receptorγ （PPARγ）, on the proliferation and differentiation of MC3T3-EI cells in vitro. Methods MC3T3-E1 cells were treated with different doses of ROSI. The effects of different concentrations of ROSI on pro- liferation of MC3T3-E1 cells were observed. The cells were cultured in the medium containing different concentra- tions of ROSI for ALP staining. Real-time PCR was used for the detection of Runx2, OB markers ALP and OCN mRNA expression in the cells cultured for 7 days. Results As compared with control group, the proliferation of MC3T3-EI cells was decreased. As compared with control group, the ALP staining in 1 μmol/L ROSI group and 5 μmol/L group was decreased. Real-time PCR showed the mRNA expression of Runx2 in 1 μmol/L ROSI group and 5 μmol/L group was decreased by （54. 7 ± 8. 2）% and （52.3 ± 7. 2）%, that of ALP decreased by （18.7± 5. 1 ）% and （37. 8 ± 8.5） %, and that of OCN decreased by （43.4± 5.6） % and （60. 4± 4. 3）% as compared with control group, respectively. Conclusion Rosiglitazone can decrease proliferation of MC3T3-EI cells and osteogen- ic activity, which is one of the key pathogenesis factors of osteoporosis in type II diabetic mellitus patients after ad- ministration of thiazolidinediones.
出处
《骨科》
CAS
2014年第1期1-4,共4页
ORTHOPAEDICS
基金
国家自然科学基金资助项目(81070691)
关键词
降血糖药
成骨细胞
细胞增殖
细胞分化
Hypoglycemic agents
Osteoblasts
Cell proliferation
Cell differentiation
